Category: All

  • Preventing progression of dry age-related macular degeneration (AMD)

    Hemera Biosciences’ dry AMD drug succeeds in Phase I safety study In December 2016, the FDA granted Hemera “safe to proceed” status for an investigational new drug application on its lead product HMR59. A Phase…


  • A new tool to assess brain function and cerebrovascular health

    Sergio Fantini has developed an innovative tool that helps in the early diagnosis and monitoring of cerebrovascular disorders.  Cerebrovascular diseases are the second leading cause of death, the second leading cause of dementia, and the…


  • Turning the corner on regenerative medicine – Silk science translates into real-world products

    Silk protein – also known as fibroin – possesses highly advantageous properties for tissue support and regeneration.  As a natural structural protein, silk can provide strength and facilitate tissue ingrowth as it slowly resorbs in…


  • Featured Medical Device Opportunity

    INFORCE™ Biopsy: One-Step Method for Incision and Forceps Biopsy Procedure During Endoscopy Sector Gastrointestinal endoscopy biopsy Development Phase Preclinical Problem Subepithelial lesions are a common finding during upper endoscopy (EGD). Of the more than 2.8…


  • Cocoon’s Bioinjectable Technology: Spinning Silk into Advancements in Osteoarthritis Therapy

    Before Ailis Tweed-Kent was CEO and Founder of Cocoon Biotech, she was a resident in internal medicine at Massachusetts General Hospital. Her clinical experience, sometimes treating patients 60 hours a week, helped her to see…


  • New Silk Medical Device Startup

    Tufts University announced that it has licensed a novel silk technology for the treatment of chronic skin wounds to Akeso Biomedical, Inc., an early stage medical device company. The technology was invented by David L….


  • KinderLab Robotics Awarded SBIR Grant

    KinderLab Robotics, Inc has received a Phase 1 Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to fund product design of a unique robot kit. KinderLab Robotics is based on over…


  • Innovative Qiaobing Xu

    Targeted drug delivery At least 100 genuine, and a large number of modified, therapeutic proteins and peptides are approved for clinical use, yet most protein and peptide pharmaceuticals on the market or under development now…


  • Tufts Tech Transfer visits Universidad de Valparaiso (Chile)

    Under its activities in global technology transfer, Tufts Tech Transfer recently visited the Universidad de Valparaiso (Chile) to provide training classes on intellectual property management and licensing to their technology transfer and research administration offices….


  • “Beads on a String” Represents Novel Approach for Neutralizing Toxins

    Researchers at Cummings School of Veterinary Medicine at Tufts University have unveiled a novel strategy for neutralizing (pathogens) unwanted molecules and clearing them from the body. The strategy utilizes chains of binding agents, like beads…


  • Enhancing Global Impact – Hosting International Technology Transfer Professionals

    In order to positively enhance the global impact of technology transfer, Tufts Tech Transfer engages in a number of targeted activities which include the hosting and teaching of international technology transfer professionals. Tufts Tech Transfer…


  • Neuroscience Collaboration with AstraZeneca

    AstraZeneca and Tufts University’s School of Medicine and Sackler School of Graduate Biomedical Sciences are collaborating as part of a three year agreement to perform cutting-edge research into biological targets in the field of neuroscience. …


  • Tufts Tech Transfer attends AUTM 2013

    Members of the Tufts Tech Transfer team recently attended the 2013 annual meeting of the Association of University Technology Managers (AUTM) which took place in San Antonio, TX. Highlights from the conference include the moderation…


  • The American Invents Act

      The Leahy-Smith America Invents Act (AIA), which is the most important change in U.S. patent legislation since 1952, was signed into law in 2011. The law is being implemented in three phases.  The most…


  • Tufts Silk Portfolio

    Biomedical engineers David Kaplan and Fiorenzo Omenetto took a material that’s been around for thousands of years — silk — and created hundreds of distinct, high-technology products and applications that could transform healthcare.

    David Kaplan, chair of biomedical engineering at Tufts University, has worked on medical applications of silk for over twenty years. In 2006 he began collaborating with Fiorenzo Omenetto, a specialist in optics, in creating silk-based nanoelectronics.


  • GliaCure

    Philip Haydon, professor and chair of the Department of Neuroscience, discovered that to achieve great payoffs in business, an entrepreneur must be tenacious and have strong convictions. The Haydon laboratory studies how astrocytes regulate synaptic transmission and the role they play in disorders of the central nervous system.


  • Chris Pirie: Solving Unmet Need

    While treating patients at the Foster Hospital for Small Animals at Cummings School of Veterinary Medicine, Chris Pirie discovered that he no longer had the proper equipment for assessing the health of the back of an animal’s eye. The Foster Hospital has a fundus camera to monitor progression of eye disease, but recent advances in digital photography had rendered the instrument obsolete.


  • Visionary David Walt

    The multitalented David Walt embodies a rare combination of entrepreneurial skill, research ability, and passion for science education. Walt, who is the Robinson Professor of Chemistry at Tufts University and a Howard Hughes Medical Institute professor, applies micro- and nanotechnology to solve urgent biological problems.


  • Pepducin Therapeutics

    The pepducin technology—discovered in the Tufts Medical Center laboratories of Athan Kuliopulos and Lidija Covic—has launched the start-up company Anchor Therapeutics and a $10 million NIH grant (to Tufts Medical Center) to test a new blood clot prevention drug.